Abbott Reaches Agreements to Resolve Portion of Litigation Over Preterm Infant Formulas

Abbott has reached agreements to resolve a portion of litigation concerning its specialty formulas for preterm infants. The company announced Tuesday that the settlements cover the "Gill" case and claims from approximately 2,000 other individuals.

The company, along with the medical community, maintains that its specialized formulas for preterm infants are safe. Abbott has repeatedly stated that regulators and medical professionals recognize the safety and necessity of these products.

Financial terms of the agreements were not disclosed. Abbott has previously stated it does not believe it is responsible for any claims regarding the use of its preterm infant formulas but has sought to resolve these legal disputes.

These settlements represent an effort to conclude protracted legal proceedings that have targeted the company's specialized child nutrition products. Abbott continues to develop and provide its products to healthcare providers and patients.